Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	PCT/GB2004/001306
Filing Date	25 March 2004
First Named Inventor	Andrew Simon CRAIG
Title	PROCESS FOR PREPARING A POLYMORPH OF ROSIGLITAZONE MALEATE
Art Unit	
Examiner Name	
Attorney Docket Number	PB60164

I hereby appoint:		
Practitioners associated with the Customer Numbers.	20462	
Or		
☐ Practitioner(s) named below:		
Name	Registration Number	
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.		
Please recognize or change the correspondence address for the	ne above-identified application to:	
☐ The address associated with the above-mentioned Custo	mer Number:	
Or		
■ The address associated with Customer Number 2046.	2	
Or		
☐ Firm or Individual Name:		
Address:		
Address:		
City:	State: Zip:	
Country:		
Telephone:	Fax:	
I am the:		
Applicant/Inventor:		
Assignee or pord of the entire interest. See 37 CFR 3.71.		
Statement under 37 GFR 3.73(b) is enclosed. (Form PTO/SB/96) SIGNATURE of Applicant or Assignee of Record		
Name: Peter John GIDDINGS To	ate: ng SEP 2005 elephone: +44 20 8047 4414	
Title and Company Attorney and Authorised Official, Glaxo Group Limited		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.		
Submit multiple forms if more than one signature is required, see below*.		
Total of: forms are submitted.		

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CRF 3.73(b)			
Applicant/Patent Owner: Glaxo Group Limited			
International Application No./Patent No.: PCT/GB2004/001306 Filed/Issue Date: 25 March 2004			
Entitled: PROCESS FOR PREPARING A POLYMORPH OF ROSIGLITAZONE MALEATE			
Glaxo Group Limited, a corporation, states that it is:			
1. It the assignee of the entire right, title, and interest; or			
2. an assignee of less than the entire right, title and interest.			
The extent (by percentage) of its ownership interest is% in the patent application/patent identified above			
by virtue of either;			
A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was			
recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a			
copy thereof is attached.			
OR			
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee			
as shown below:	The state of the s		
1. From: To:	100 1 000		
The document was recorded in the United States Pate	ent and Trademark Office at		
Reel , Frame	_, or for which a copy thereof is attached.		
2. From: To: To: The document was recorded in the United States Pate	17-1-1-06		
Reel , Frame	_, or for which a copy thereof is attached.		
3. From: To: The document was recorded in the United States Patent and Trademark Office at			
	or for which a copy thereof is attached.		
Additional documents in the chain of title are listed o			
[X] Copies of assignments or other documents in the chain of title are			
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment			
Division in accordance with 37 CRF Part 3, if the assignment is to be recorded in the records of the USPTO.			
See MPEP 302.08]			
The undersigned (whose titles supplied below) is authorized to act on	habalf of the againman		
The undersigned (whose the issupplied below) is authorized to act on	behalf of the assignee.		
() -acc.			
	06 SEP 2005		
Signature	Date		
Significan			
Peter John GIDDINGS	+44 20 8047 4414		
Printed or Typed Name	Telephone Number		
	£		
Attorney and Authorised Official			
Title			

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

WHEREAS I/WE, Andrew Simon CRAIG, Robert Gordon GILES, Tim Chien Ting HO and Michael John SASSE of Tonbridge, Kent, GB (hereinafter called "the inventor(s)") have invented or discovered "PROCESS FOR PREPARING A POLYMORPH OF ROSIGLITAZONE MALEATE" (hereinafter called "the invention") for which a patent application no. 0307259.2 was filed on 28 March 2003 in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

(PCT/GB2004/001306 filed 25 March 2004)

WHEREAS the invention, being made in the course of my employment, belongs to my/our employer, namely GLAXOSMITHKLINE SERVICES UNLIMITED a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, and

WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from GLAXOSMITHKLINE SERVICES UNLIMITED the whole right, title and interest in and to the invention and the application, and

GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED have authorised and requested my/our making the application, and

WHEREAS GLAXO GROUP LIMITED a company organised and existing under and by virtue of the laws of England and Wales and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England, is desirous of acquiring from GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED the whole right, title and interest in and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by GLAXOSMITHKLINE SERVICES UNLIMITED of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to GLAXOSMITHKLINE SERVICES UNLIMITED. GLAXOSMITHKLINE SERVICES

UNLIMITED in turn hereby assigns and transfers to GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED its whole right, title and interest in and to the invention and the application. GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to GLAXO GROUP LIMITED its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby authorise and request any patent arising therefrom in the United States of America be issued to GLAXO GROUP LIMITED.

AND GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in GLAXO GROUP LIMITED, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IN WITNESS whereof and with effect from 28 March 2003 the inventor(s) and Peter John GIDDINGS as Attorney of both GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED by virtue of Powers of Attorney granted by GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED respectively have hereunto set their respective hands.

SIGNED by Andrew Simon CRAIG:

Herry

Date: 25th November 2005

SIGNED by Rachel Helen GILES: as executor of the estate of Robert Gordon GILES (deceased)

Date: 18/11/05

SIGNED by Jonathan Robert Saville SMITHERS: as executor of the estate of Robert Gordon GILES (deceased) Date:
SIGNED by Tim Chien Ting HO:
Date: 25th Nov 2005
SIGNED by Michael John SASSE:
Date: 245 Novem (2005)
SIGNED by Peter John GIDDINGS as the Attorney of each of GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED:
Date: 11 JAN 2006